Viking Therapeutics $VKTX Phase 2 Data Shows 12.2% Weight Loss in 13 Weeks with Oral Obesity Drug

Viking Therapeutics has unveiled compelling Phase 2 trial results for its oral obesity drug VK2735, demonstrating substantial weight loss potential that could reshape the competitive landscape in metabolic treatments. The data reveal mean weight reductions of up to 12.2% over just 13 weeks, with an impressive 97% of participants achieving at least 5% body weight loss. Yet, the trial also highlighted challenges with gastrointestinal side effects, contributing to elevated discontinuation rates, underscoring the delicate balance between efficacy and tolerability in this burgeoning market.

Breakdown of the Phase 2 VENTURE-Oral Trial Results

The Phase 2 VENTURE-Oral study evaluated VK2735, a dual GLP-1/GIP receptor agonist administered as a daily oral tablet, in patients with obesity. Over 13 weeks, the highest dose cohort achieved a placebo-adjusted mean weight loss of 12.2%, translating to an absolute reduction of approximately 12 kilograms from baseline. This performance positions VK2735 as a frontrunner among oral candidates, potentially rivalling the efficacy of injectable therapies while offering the convenience of pill-based dosing.

Notably, the trial’s responder rates were striking: 97% of patients on VK2735 reached the clinically meaningful threshold of 5% weight loss, and 80% in the top dose group exceeded 10%. These figures suggest a broad efficacy profile, which could appeal to a wide patient population seeking non-invasive weight management options. Analysts have noted that such rapid and consistent results in a relatively short timeframe could accelerate VK2735’s path to market, provided subsequent studies confirm durability and safety.

Safety Profile and Discontinuation Concerns

While the efficacy data are encouraging, the trial did not escape the common pitfalls of GLP-1 class drugs. Gastrointestinal adverse events, including nausea, vomiting, and diarrhoea, were prevalent, leading to higher discontinuation rates compared to placebo. Specifically, around 15–20% of participants withdrew due to these side effects, a figure that aligns with industry patterns but raises questions about long-term adherence. Viking reported that most events were mild to moderate, with no severe cases, and the company emphasised that tolerability improved over time as patients adjusted to the dosing regimen.

This aspect invites comparison with established players like Novo Nordisk’s semaglutide and Eli Lilly’s tirzepatide, where similar GI issues have been managed through dose titration. For VK2735, refining the escalation protocol in future trials could mitigate dropouts, potentially enhancing its commercial viability. Investors should monitor how Viking addresses these tolerability hurdles, as they could influence prescribing patterns and market share in a sector projected to exceed $100 billion by 2030.

Market Implications and Competitive Positioning

The obesity drug market is heating up, with oral formulations emerging as a key battleground to overcome the injection fatigue associated with current leaders. VK2735’s data come at a time when rivals like Eli Lilly’s orforglipron have faced setbacks, including delays in Phase 3 timelines due to manufacturing issues. Viking’s oral candidate, by contrast, appears on track for advancement, with plans for Phase 3 initiation potentially in 2026, assuming regulatory alignment.

From a valuation perspective, Viking Therapeutics trades at a forward price-to-earnings ratio of -27.87, reflecting its pre-revenue status and ongoing clinical investments. The company’s market capitalisation stands at $4.73 billion, with shares outstanding at 112.45 million. Recent trading data as of 19 August 2025 show the stock opening at $40.40, reaching a day high of $42.23, and closing the previous session at $40.03. This positions Viking amid a volatile 52-week range of $18.92 to $81.73, highlighting investor sensitivity to clinical milestones.

Analyst sentiment remains bullish, with a consensus rating of 1.6 (Buy) from credible sources such as Cantor Fitzgerald and Stifel, who have reiterated overweight and buy recommendations with price targets around $95 to $104. These forecasts are predicated on VK2735’s potential to capture a slice of the oral obesity segment, where convenience could drive higher compliance rates than injectables.

Broader Industry Trends and Risks

The surge in obesity treatments reflects a global health crisis, with over 1 billion individuals affected worldwide according to World Health Organization estimates from 2022. Dual agonists like VK2735 target multiple pathways to suppress appetite and improve metabolic function, offering advantages over single-mechanism drugs. Historical data from Phase 1 trials of VK2735, reported in March 2024, showed up to 5.3% weight loss in 28 days at lower doses, building a foundation for the escalated efficacy seen in Phase 2.

However, risks abound. Higher discontinuations due to GI effects could cap uptake, especially if competitors refine their profiles. Regulatory scrutiny on cardiovascular safety and long-term outcomes will be pivotal; Viking’s ongoing studies must demonstrate sustained benefits without unforeseen complications. Moreover, manufacturing scalability for an oral tablet could present hurdles, as seen in peers’ experiences.

In a model-based forecast by Jefferies analysts, VK2735 could achieve peak sales of $5–7 billion if it secures 10–15% market penetration by 2035, assuming approval and favourable reimbursement. This projection hinges on comparative trials against benchmarks like Lilly’s orforglipron, where VK2735’s faster weight loss trajectory might confer an edge.

Investor Considerations

For investors, VK2735’s Phase 2 readout signals a high-reward opportunity tempered by biotech volatility. The drug’s profile—robust weight loss with manageable but notable side effects—mirrors the trade-offs in this class, yet its oral delivery could disrupt the status quo. With earnings per share estimates at -1.51 for the forward period and a book value of 7.08, Viking’s financial health supports further development, backed by a cash runway extending into 2027.

• Efficacy Edge: 12.2% mean weight loss in 13 weeks outpaces many oral peers in similar timelines.
• Tolerability Trade-off: GI side effects drove discontinuations, necessitating protocol optimisations.
• Market Potential: Positions Viking to challenge injectables in a $100bn+ arena.
• Analyst Outlook: Buy ratings with targets implying significant upside from current levels.

As Viking progresses VK2735 towards late-stage trials, the focus will shift to durability data and head-to-head comparisons. While the path ahead includes regulatory and competitive risks, the Phase 2 results affirm the drug’s promise, potentially rewarding patient capital in this dynamic sector.

References

• BioSpace. (2024). Viking touts promising Phase I weight loss data for obesity pill candidate. https://www.biospace.com/drug-development/viking-touts-promising-phase-i-weight-loss-data-for-obesity-pill-candidate
• Clinical Trials Arena. (2024). Viking VK2735 II trial obesity. https://www.clinicaltrialsarena.com/news/viking-vk2735-ii-trial-obesity/
• Inkl. (2024). Viking’s oral obesity drug poised to gain ground after Eli Lilly’s orforglipron setback. https://inkl.com/news/viking-s-oral-obesity-drug-poised-to-gain-ground-after-eli-lilly-s-orforglipron-setback-analyst
• Investing.com. (2024). Viking Therapeutics stock falls after obesity drug trial results. https://www.investing.com/news/stock-market-news/viking-therapeutics-stock-falls-after-obesity-drug-trial-results-93CH-4199781
• Investing.com. (2024). Viking’s oral obesity drug shows promising weight loss results. https://www.investing.com/news/company-news/vikings-oral-obesity-drug-shows-promising-weight-loss-results-93CH-4199763
• Investing.com. (2024). Oppenheimer reiterates outperform rating on Viking Therapeutics stock. https://investing.com/news/analyst-ratings/oppenheimer-reiterates-outperform-rating-on-viking-therapeutic-stock-93CH-4197062
• MedCity News. (2024). Viking Therapeutics oral obesity drug VK2735. https://medcitynews.com/2024/11/viking-therapeutics-oral-obesity-drug-vk2735-glp1-gip-vktx
• PR Newswire. (2024). Viking Therapeutics announces positive top-line results from Phase 2 VENTURE-Oral dosing trial of VK2735. https://prnewswire.com/news-releases/viking-therapeutics-announces-positive-top-line-results-from-phase-2-venture-oral-dosing-trial-of-vk2735-tablet-formulation-in-patients-with-obesity-302533355.html
• PR Newswire. (2024). Viking Therapeutics reports new data from VK2735 obesity program at ObesityWeek. https://www.prnewswire.com/news-releases/viking-therapeutics-reports-new-data-from-vk2735-obesity-program-at-obesityweek-2024-302294915.html
• StockTitan. (2024). Viking Therapeutics announces positive top-line results from Phase 2. https://www.stocktitan.net/news/VKTX/viking-therapeutics-announces-positive-top-line-results-from-phase-2-gsafogiorg9a.html
• Viking Therapeutics. (2024). Metabolic disease program – VK2735. https://vikingtherapeutics.com/pipeline/metabolic-disease-program/vk2735/
• Viking Therapeutics Investor Relations. (2024). Results from Phase 1 clinical trial of oral VK2735. https://ir.vikingtherapeutics.com/2024-03-26-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Oral-Tablet-Formulation-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735
• Viking Therapeutics Investor Relations. (2024). New data from VK2735 obesity program. https://ir.vikingtherapeutics.com/2024-11-04-Viking-Therapeutics-Reports-New-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2024
• Yahoo Finance. (2024). 1 beaten-down stock could surge. https://finance.yahoo.com/news/1-beaten-down-stock-could-125500064.html
• X.com (2024). Sentiment/analysis posts: Pharmdca, Dr. Angela Rasmussen, Dr. Hoenderkamp, Jason V. Holmes, Trent Kelp. (Various URLs from citations list)